# Brian P. McVeigh

> Brian P. McVeigh is chairman, CEO and co-founder of Code Biotherapeutics, chairman of Genisphere and a US venture partner at 4BIO Capital. His background includes 25 years at GSK, leadership of worldwide business-development transactions and investment management, and executive roles at KBP Biosciences and Zafgen. He studied accounting and finance at La Salle and earned an MBA at Villanova, with additional credentials from Saint Joseph’s and Wharton.

- **Role:** Chairman, Chief Executive Officer and Co-Founder at Code Biotherapeutics
- **Organizations:** Code Biotherapeutics, Genisphere, 4BIO Capital, GlaxoSmithKline, KBP Biosciences, Zafgen
- **Education:** Bachelor of Science degrees in Accounting and Finance, La Salle University, MBA, concentration in Finance, Villanova University, Post-MBA Certificate in Pharmaceutical Marketing, Saint Joseph’s University, Certificate of Professional Development, Wharton School, University of Pennsylvania
- **Known for:** Personally led assessment and negotiation of more than two dozen significant transactions during his GSK business-development tenure., Formed and led a global GSK organization overseeing more than 100 business-development transactions., Managed more than $500 million in invested and committed GSK capital; the portfolio delivered more than $650 million in realized returns under his leadership.

## Career timeline

- **1992-2017** — Held successive roles at GSK; final position was Vice President of Worldwide Business Development Transactions and Investment Management.
- **2017-2018** — CEO and board director of KBP Biosciences, December 2017-April 2018.
- **2018** — Became Zafgen Chief Business Officer effective May 29.
- **2020** — Led Zafgen’s merger with Chondrial Therapeutics to form Larimar Therapeutics; identified as Code Bio co-founder and executive chairman by July.
- **2020** — Appointed a US venture partner at 4BIO Capital on July 1.
- **2021** — Code Bio announced $10 million seed financing on April 20, identifying McVeigh as chairman, CEO and co-founder.
- **2022** — Code Bio announced $75 million Series A financing on June 7.
- **2023** — Participated in an early-stage VC fundraising podcast panel published February 10; presented at BIO on June 6.
- **2024** — Publicly promoted his October 7 Meeting on the Mesa presentation.

## Achievements

- Personally led assessment and negotiation of more than two dozen significant transactions during his GSK business-development tenure.
- Formed and led a global GSK organization overseeing more than 100 business-development transactions.
- Managed more than $500 million in invested and committed GSK capital; the portfolio delivered more than $650 million in realized returns under his leadership.
- Co-founded Code Biotherapeutics, which announced a $10 million seed round in 2021 and $75 million Series A in 2022.
- Certified Public Accountant, Certified Management Accountant and Certified Licensing Professional.

## Latest updates

- **2024-10** — Promoted his October 7 presentation at Meeting on the Mesa on LinkedIn.
- **2023-06** — Listed as a Code Biotherapeutics presenter at BIO International Convention on June 6.
- **2023-02** — Appeared on an early-stage VC funding panel for The Phase 3 Biotech Leadership Podcast.

## Links

- Website: https://www.codebiotx.com/leadership
- LinkedIn: https://www.linkedin.com/in/brian-mcveigh-6562555

---

Profile page: https://yespress.io/brian-p-mcveigh
Published by YesPress — https://yespress.io
Last updated: 2026-10-15